GLP-1 Drugs Cut Heart Risks in Overweight Diabetics, Safeguard Kidneys for All: JAMA
Taiwan: A recent study has found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes delivers body mass index (BMI)-dependent cardiovascular benefits and consistent kidney protection. The findings, published in JAMA Network Open, suggest that while heart-related benefits are more pronounced in individuals with a higher BMI, kidney […]